DRUG
Bivalirudin
After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
Status
Active, not recruiting
Phase
Not applicable
Enrollment
206
Locations
1
Results
Not posted
Publications
1
Study summary
Among patients with stable ischemic heart disease who are referred for coronary angiography, a substantial proportion have non-obstructive coronary artery disease (CAD). Ischemia based on symptoms or stress testing may be due to coronary microvascular dysfunction in up to 40% of these patients. However, the mechanisms and optimal treatment of coronary microvascular dysfunction are unknown. Aberrant platelet activity and inflammation have been hypothesized as mechanisms of microvascular dysfunction. Investigators plan to evaluate association between platelet activity, inflammation, and coronary microvascular dysfunction in stable women referred for coronary angiography, and to identify non-invasive correlates of coronary microvascular dysfunction in these patients.
The objectives of this study are to 1. Investigate platelet activity and inflammation in patients with and without coronary microvascular disease who are referred for coronary angiography for the evaluation of stable ischemic heart disease and are found to have non-obstructuve epicardial CAD 2. To identify correlates of coronary microvascular dysfunction in non coronary microvascular beds that can be characterized in vivo.
Interventions
DRUG
After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.
DRUG
An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.
DRUG
Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.
DEVICE
Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.
DEVICE
Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
Timeline
First posted
May 25, 2018
Study start
Jun 29, 2018
Primary completion
Jun 30, 2025
Study completion
Jun 30, 2026
Results posted
Not reported
Registry updated
Nov 28, 2025
Outcomes
Platelet Activity measured by the Index of Microcirculatory Resistance (IMR)
Time frame · 12 Months
Measure of Inflammation measured by the Index of Microcirculatory Resistance (IMR)
Time frame · 12 Months
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Adult women age ≥18 years referred for coronary angiography * Stable ischemic heart disease, defined by ischemic symptoms and/or myocardial ischemia by stress testing * Administration of aspirin therapy prior to cardiac catheterization Exclusion Criteria: Pre-Cath Exclusion criteria: * Active bleeding and/or bleeding diathesis * Anemia (hemoglobin \<9 mg/dl) * Known thrombocytosis (platelet count \>500,000) * Know thrombocytopenia (platelet count \<100,000) * NSAIDs (e.g., ibuprofen, naproxen) within 3 days * Platelet antagonists other than aspirin and thienopyridines, within 7 days * Prior percutaneous coronary intervention or coronary artery bypass grafting * Acute myocardial infarction within 3 months * Severe valvular heart disease * Cardiogenic shock or mechanical circulatory support * New York Heart Association (NYHA) Functional Class III or IV heart failure * Ejection Fraction \<40% * Hypertrophic obstructive cardiomyopathy or severe left ventricular hypertrophy * Pregnancy * Contraindication to intravenous infusion of adenosine during coronary angiography, due to known hypersensitivity to adenosine, known or suspected bronchoconstrictive or bronchospastic lung disease (severe asthma), second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or sinus node disease, such as sick sinus syndrome or symptomatic bradycardia, Angiographic Exclusion criteria: * Obstructive CAD (≥50% luminal obstruction in ≥1 major epicardial coronary arteries by invasive coronary angiography) * Unfavorable coronary artery anatomy for guidewire positioning (as determined by the angiographer or PI)
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
New York University School of Medicine
New York, New York, United States
Related trials
Duke University · Coronavirus Infection (COVID-19) · Pulmonary Arterial Hypertension
Not applicable
Recruiting
5,000
2026-07
Sydney Local Health District · Extracorporeal Membrane Oxygenation Complication
Phase 2
Recruiting
80
2026-05
Xiaotong Hou · Extracorporeal Membrane Oxygenation Complication
Not applicable
Recruiting
154
2026-04
Shenyang Northern Hospital · Percutaneous Coronary Intervention · High Bleeding Risk
Phase 4
Not yet recruiting
5,270
2026-02
Stanford University · Heart Failure · Cardiogenic Shock
Phase 2
Recruiting
50
2026-01
Shenyang Northern Hospital · ST Elevation Myocardial Infarction
Not applicable
Completed
6,016
2025-08
Peking University First Hospital · Coronary Microvascular Dysfunction
Phase 4
Recruiting
70
2025-08
Boston Children's Hospital · Drug Effect
Not applicable
Recruiting
30
2025-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.